Running the Marathon: Updated Evidence on Sequential EGFR TKI Approach in NSCLC (Presentation)
Speaker: Dr. Maximilian Hochmair
Document ID: PC-MY-101628
Dr Maximillian Hochmair discussed about the head-to-head comparison trials on efficacy and safety of different EGFR-TKI as well as the clinical benefits of prescribing afatinib as first-line then followed by osimertinib in patients who acquired EGFR resistance mutation T790M.
Speaker
Dr. Maximilian Hochmair
Head of Respiratory Oncology Unit
Depatment of Respiratory & Critical care Medicine,
Klinik Floridsdorf Krankenhaus Nord, Brunnerstrabe 68
1210 Vienna/Austria
Effectiveness of Dose Modification Strategies with Afatinib: A Real-World Experience
Speaker: Assoc Prof Dr Ho Gwo-Fuang
